Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients
- PMID: 24013581
- DOI: 10.1093/annonc/mdt364
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients
Abstract
Background: Emerging literature data are showing that a change in human epidermal growth factor receptor (HER2) status adversely affects breast cancer patient's prognosis. The aim of this study was to evaluate the prognostic impact of HER2 loss in patients with HER2-positive disease treated with neoadjuvant therapy with or without anti-HER2 agents.
Methods: One hundred and seven consecutive HER2-positive patients were identified from a prospectively maintained database. The first cohort includes 40 patients treated with chemotherapy (CT) alone. The second cohort includes 67 patients treated with neoadjuvant CT plus anti-HER2 agents (trastuzumab and/or lapatinib). HER2 expression was evaluated by immunihistochemistry or fluorescence in situ hybridization on pretreatment core biopsy and on surgical specimen after therapy.
Results: The rates of pathologic complete response (pCR) and breast-conserving surgery were higher in the CT + anti-HER2 cohort. A loss of HER2 expression was observed in 40% of the patients with residual disease after CT alone versus 14.7% of the patients after CT + anti-HER2 agents (P = 0.019). Patients not achieving a pCR have a significant increase in the risk of relapse when compared with those achieving a pCR (hazard ratio [HR] 9.55, P = 0.028). Patients with HER2 loss tended to have a higher risk of relapse as comparing to patients with maintained HER2 positivity (HR 2.41, P = 0.063).
Conclusion: The pCR is confirmed as a powerful predictor of long-term outcome. The rate of HER2 loss is higher in patients receiving neoadjuvant CT without anti-HER2 agents. HER2 status on residual disease after preoperative therapy can be helpful in selecting patients at different risk of relapse, to be included in prospective trial exploring further adjuvant therapy.
Keywords: HER2 change; breast cancer; discordance; primary systemic therapy; trastuzumab.
Similar articles
-
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.J Clin Oncol. 2012 May 20;30(15):1796-804. doi: 10.1200/JCO.2011.38.8595. Epub 2012 Apr 16. J Clin Oncol. 2012. PMID: 22508812
-
Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.Breast Cancer Res Treat. 2017 Jan;161(2):259-267. doi: 10.1007/s10549-016-4064-9. Epub 2016 Nov 24. Breast Cancer Res Treat. 2017. PMID: 27885439
-
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.J Clin Oncol. 2011 Sep 1;29(25):3351-7. doi: 10.1200/JCO.2010.31.4930. Epub 2011 Jul 25. J Clin Oncol. 2011. PMID: 21788566 Clinical Trial.
-
Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.Cancer Treat Rev. 2017 Jun;57:8-15. doi: 10.1016/j.ctrv.2017.04.005. Epub 2017 May 2. Cancer Treat Rev. 2017. PMID: 28525810 Review.
-
Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature.Breast. 2023 Dec;72:103586. doi: 10.1016/j.breast.2023.103586. Epub 2023 Oct 3. Breast. 2023. PMID: 37812963 Free PMC article. Review.
Cited by
-
Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China.World J Surg Oncol. 2024 Apr 6;22(1):88. doi: 10.1186/s12957-024-03365-x. World J Surg Oncol. 2024. PMID: 38582875 Free PMC article.
-
Tumor heterogeneity and clinically invisible micrometastases in metastatic breast cancer-a call for enhanced surveillance strategies.NPJ Precis Oncol. 2024 Mar 29;8(1):81. doi: 10.1038/s41698-024-00572-3. NPJ Precis Oncol. 2024. PMID: 38553598 Free PMC article.
-
Decreased HER2 expression in endometrial cancer following anti-HER2 therapy.J Pathol. 2024 Feb;262(2):129-136. doi: 10.1002/path.6230. Epub 2023 Nov 27. J Pathol. 2024. PMID: 38013631
-
Changes in HER2 status and survival outcomes in patients with non-pathological complete response after neoadjuvant targeted treatment.Medicine (Baltimore). 2023 Sep 29;102(39):e34903. doi: 10.1097/MD.0000000000034903. Medicine (Baltimore). 2023. PMID: 37773875 Free PMC article.
-
Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases.Br J Cancer. 2023 Oct;129(8):1274-1283. doi: 10.1038/s41416-023-02403-x. Epub 2023 Aug 21. Br J Cancer. 2023. PMID: 37604930 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous